What is Jalra used for?

Jalra is indicated for Diabetes mellitus type 2.

What development phase is Jalra in?

Jalra is FDA-approved (marketed).

What is the generic name of Jalra?

VILDAGLIPTIN is the generic (nonproprietary) name of Jalra.

Last reviewed 2026-04-20 · How we verify

Jalra (VILDAGLIPTIN)

FDA-approved approved Small molecule Quality 37/100

At a glance

Generic name	VILDAGLIPTIN
Drug class	vildagliptin
Target	Dipeptidyl peptidase 4
Modality	Small molecule
Therapeutic area	Metabolic
Phase	FDA-approved
First approval	2007
Annual revenue	159

Approved indications

Diabetes mellitus type 2

Common side effects

No common side effects on file.

Key clinical trials

A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM (PHASE4)
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome (PHASE2,PHASE3)
Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients (PHASE2)
Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors (PHASE4)
The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients (PHASE1,PHASE2)
Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia (PHASE2)
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results
SEC EDGAR	Revenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Jalra CI brief — competitive landscape report
Jalra updates RSS · CI watch RSS